Zoegenics' (NASDAQ:ZGNX) Zohydro has been contentious since well before its approval by the FDA. After all, the FDA's advisory committee voted overwhelmingly against approval -- and the FDA then approved the drug despite that vote! The drug is indicated for the management of pain sufficiently severe to require around-the-clock daily opioid treatment for the long term, when other treatment options are insufficient.
Since its approval last year, members of Congress, 28 attorneys-general, and most recently Massachusetts Governor Deval Patrick have weighed in against the drug, citing concerns about the drug not being tamper proof -- and therefore open to abuse. In late March, Governor Patrick issued an executive order declaring a state of emergency in Massachusetts regarding heroin and opiate addiction and banning sales of Zohydro in the commonwealth.
This week, Zoegenics challenged the executive order in court, with CEO Roger Hawley saying that "we are convinced the decision [to ban Zohydro] was driven by factual inaccuracies about the science and the data." A ruling is expected soon from District Court Judge Rya Zobel, who noted (per the Boston Globe) that "I think, frankly, the governor is out of line on this."
In this video from Tuesday's Market Checkup, Motley Fool health care analysts David Williamson and Michael Douglass discuss Zohydro and what's next for the embattled painkiller and its parent company.
3 stocks poised to be multi-baggers
Looking for stocks with the growth opportunity but without all the bad press? The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multi-bagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.